Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA6 | P23280 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13960038 | 0.77 | ESR1 (0.39) | ESR2ALDH1A1LMNAPBRM1ESR1 | |
| SCHEMBL4450099 | 0.73 | ESR1 (0.36) | ESR2KDM4EALDH1A1LMNAALOX12 | |
| SCHEMBL4450658 | 0.68 | ESR1 (0.42) | ESR2ESR1MAPKAPK2MAOB | |
| SCHEMBL13959560 | 0.67 | MAOA (0.39) | ESR2KDM4EALDH1A1LMNAALOX12 | |
| SCHEMBL13958284 | 0.65 | ESR1 (0.35) | ESR2ESR1MAPKAPK2MAOBHSD17B3 | |
| SCHEMBL9170046 | 0.64 | ESR2 (0.63) | ESR2CHEK1WEE1ESR1TYR | |
| SCHEMBL27930528 | 0.62 | ESR2 (0.55) | ESR2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL10429209 | 0.62 | ESR2 (0.55) | ESR2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL18884183 | 0.61 | BCHE (0.41) | KDM4EALDH1A1MAPK1 | |
| SCHEMBL20839172 | 0.60 | CA12 (0.65) | KDM4EALDH1A1LMNASMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | WYETH (US) | 2006-01-05 | — | — | US | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1761513-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | Wyeth (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006007503-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | WYETH (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | ESR1, ESRRA, ESR2 | ESR2 3/4885CA1 1396/4885CA2 1480/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR2 5/4885CA1 3298/4885CA2 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.